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Abstract 
Tumor microenvironments present significant barriers to penetration by antibodies and 
immunoconjugates and are difficult to study in vitro. Cells cultured as monolayers typically 
exhibit less resistance to therapy than those grown in vivo. Therefore, it is important to de-
velop an alternative research model that better represents in vivo tumors. We have developed 
a protocol to produce multicellular spheroids, a simple and more relevant model of in vivo 
tumors that allows for further investigations of the microenvironmental effects on drug 
penetration and tumor cell killing. The protocol is used to produce in vitro three-dimensional 
tumor spheroids from established human cancer cell lines and primary cancer cells isolated 
from patients without the use of any extracellular components. To study the ability of tu-
mor-targeting immunoconjugates to penetrate these tumor spheroids in vitro, we have used an 
immunotoxin targeting mesothelin, a surface protein expressed in malignant mesotheliomas. 
This method for producing consistent, reproducible 3D spheroids may allow for improved 
testing of novel monoclonal antibodies and other agents for their ability to penetrate solid 
tumors for cancer therapy. 
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INTRODUCTION 
Treatment of solid tumors remains a major chal-
lenge despite the availability of a vast number of an-
ti-cancer agents. Antibody-based therapies represent 
a promising new approach for treating solid tumors. 
However, a major challenge involves delivering suf-
ficient amounts of antibodies and immunoconjugates 
within  tumor  masses.  For  an  anti-cancer  antibody 
agent to be successful, it must (a) be effective in the 
tumor  microenvironment,  and  (b)  reach  the  tumor 
cells in optimal quantities to exert a therapeutic ef-
fect5. Tumors are more resistant to therapy than can-
cer  cells  cultured  as  monolayers.  This  can  be  ex-
plained  by  “multicellular  resistance,”  a  mechanism 
for  drug  resistance  attributed  to  cell-cell  contacts, 
cell-matrix contacts, and the three-dimensional (3D) 
shape found in tissue5. The majority of the ~1013 cells 
in the human body are only within a few cell diame-
ters of a blood vessel. This feature facilitates the de-
livery of oxygen and nutrients to the cells that form 
the tissues of the body (Fig. 1)5 and also enables the 
efficient delivery of most medicines.   
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Figure 1. Schematic overview of the in vivo tumor and the in vitro tumor spheroid. Comparison of the com-
ponents between a tumor and spheroid model. 
 
In  light  of  this,  the  solid  tumor  microenviron-
ment has several major characteristics, including hy-
poxia,  large  distances  between  blood  vessels,  high 
interstitial fluid pressure, structure and composition 
of  the  extracellular  matrix,  and  cell–cell  adhesion. 
Overall,  these  features  of  the  tumor  microenviron-
ment limit the delivery of anticancer drugs to cancer 
cells that are situated far from blood vessels. Multi-
cellular resistance acquired by tumor cells may con-
tribute to difficulties in translating promising findings 
from  in  vitro  studies  into  clinical  therapy.  In  vitro 
multicellular cancer spheroids have begun to bridge 
the  complexity  gap  between  monolayer  cell  culture 
and in vivo tumors and have become valuable models 
in  the  study  of  drug  resistance.  Spheroids  exhibit 
many  features  of  the  tumor  microenvironment  and 
model  the  avascular  region  of  tumors  that  is  de-
pendent  on  diffusion  (Fig.  1)4.  A  simple,  reliable, 
high-throughput  and  less  expensive  in  vitro  tumor 
model  would  be  useful  for  characterizing  and 
screening antibodies and immunoconjugates for can-
cer therapy. 
Here, we describe a detailed protocol to establish 
an in vitro 3D tumor spheroid model. This model can 
be used to identify potential new therapeutic targets 
that are highly expressed in mesothelioma cells in 3D 
spheroids,  but  not  in  monolayers,  and  therefore  be 
relevant in the 3D tumor. Furthermore, this protocol 
may be easily applied to in vitro studies of other tu-
mor-targeting  antibodies  and  immunoconjugates  in 
vitro. It may also be a useful system for screening tu-
mor penetrating monoclonal antibodies by antibody 
engineering technologies such as phage display 7. 
Development of the protocol 
Most studies of anticancer drugs consider only 
cellular and/or genetic mechanisms at the level of the 
single  cell.  However,  drug  penetration  is  a  highly 
important additional mechanism and requires a more 
complex  cellular  environment  to  study.  Indeed,  in 
vitro  spheroid  models  have  become  the  most  com-
monly  used  tools  to  assess  drug  penetration.         
Although animal studies, when feasible, hold the ad-
vantage of mimicking the clinical environment most 
closely,  in vitro  spheroids  offer  the  benefit  of  being  Journal of Cancer 2011, 2 
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able to examine the distribution of drugs in the ab-
sence of complicating factors such as pharmacokinet-
ics, which often differ between mice and humans. Not 
only are tumor spheroids an excellent model to eval-
uate  drug  penetration,  they  play  an  increasingly 
meaningful role in drug discovery and development.  
In 2006, Ivascu and Kubbies at Roche Pharma-
ceutical Research Oncology in Germany first reported 
a simple method to generate tumor spheroids for po-
tential  high-throughput  functionality  and  toxicity 
analysis.4  Briefly,  a  defined  number  of  cancer  cells 
ranging from 1,000 to 20,000 were seeded into wells of 
poly(2-hydroxyethylmethacrylate)–coated,  96-well, 
round- or conical-bottom plates in standard growth 
medium and centrifuged for 10 minutes at 1000 x g. 
Within 24 hours of culturing, this procedure gener-
ated individual spheroids in each well with homoge-
neous sizes, morphologies, and stratification of pro-
liferating cells found in the rim that also include dying 
cells in the core region.4 In addition, by adding base-
ment membrane extract Matrigel to some cell lines, 
they were able to improve the structure from an ag-
gregate to spheroid morphology. In 2008, after evalu-
ating  several  techniques,  V.  Courtney  Broaddus’ 
group  at  the  University  of  California  San  Francisco 
(USA)  first  established  mesothelioma  spheroids  for 
the study of apoptotic resistance using multicellular 
spheroids1, modifying the method originally reported 
by  Ivascu  and  Kubbies.1  Interestingly,  although 
Broaddus’ study did not use any basement membrane 
extract, they found the formation of spheroids to be 
stably intact.  
 Our laboratory at the National Cancer Institute 
(NCI) focuses on producing human monoclonal an-
tibodies (mAbs) for the development of cancer ther-
apy. Although leukemia treatments involving mAbs 
have been in clinical use for years, this approach has 
not been as successful for solid tumors. The prolifera-
tion of tumor cells forces blood vessels apart, reducing 
vascular  density  and  creating  a  population  of  cells 
distant  (>100μm)  from  vessels.5  Drugs  generally  do 
not penetrate further than three to five cell diameters 
from blood vessels, thereby depriving more distantly 
located tumor cells of any drugs. Penetrating antibody 
technology is increasingly seen by many to be the holy 
grail of antibody therapy. A limitation in our ability to 
identify and evaluate effective penetrating antibody 
reagents has been the lack of an in vitro model that 
recapitulates the features of a solid tumor. In the last 
two years, in collaboration with our group, the Taka-
yama  laboratory  at  the  University  of  Michigan  has 
produced  two  publications  related  to  3D  spheroid 
cultures  10,  11.  One  study  established  co-cultures  by 
introducing different types of cells on the membrane 
or in the bottom chamber of commercially available 
Transwells. They found that cancer cells formed 3D 
spheroids while maintaining their viability and used 
this  procedure  to  evaluate  mouse  embryonic  stem 
(mES)  cell  differentiation  based  on  heterogeneous 
cell-cell  interactions11.  Co-culture  of  mES  cells  and 
HepG2 human hepatocellular cancinoma (HCC) cells 
decreased SOX17 expression of mES cells, and direct 
cell-cell contact further decreased SOX17 expression, 
indicating  that  co-culture  with  HepG2  cells  inhibits 
endoderm  differentiation.  Another  study  described 
high-throughput 3D spheroid culture and drug test-
ing  using  a  384-well  format  hanging  drop  culture 
plate10.  
In collaboration with V. Courtney Broaddus, we 
made  a  3D  spheroid  model  culture  using  a  human 
mesothelioma cell line and primary cell lines isolated 
from the ascites of malignant mesothelioma patients. 
Using this model, we treated spheroids with SS1P, a 
recombinant immunotoxin targeting mesothelin6, and 
evaluated  how  the  microenvironment  affected  the 
ability of the drug to penetrate a 3D cancer cell mass 
and kill cancer cells.8 Mesothelin is highly expressed 
in  mesothelioma  and  several  other  human  cancers, 
including  pancreatic  adenocarcinomas,  ovarian  can-
cers,  lung  adenocarcinomas  and  cholangiocarcino-
ma.2, 3, 9 Although mesothelioma cells grown as mon-
olayers or as spheroids express comparable levels of 
mesothelin, we observed that spheroids were at least 
100 times less sensitive to SS1P and that penetration 
within  spheroids  was  limited  after  four  hours.  The 
core area of spheroids revealed a substantial number 
of tight junctions, along with a significant increase in 
expression  of  E-cadherin,  a  protein  involved  in  the 
assembly  and  sealing  of  tight  junctions  and  highly 
expressed  in  malignant  mesothelioma.  Moreover, 
siRNA  silencing  and  antibody  inhibition  targeting 
E-cadherin  enhanced  SS1P  immunotoxin  therapy  in 
vitro.8  
Advantages and limitations of the present 
protocol 
3D spheroid culture is often complicated to fol-
low  and  varies  frequently  according  to  individual 
practices. It can be cumbersome for labs with limited 
resources  and  expensive  to  manage.  However,  it  is 
worthwhile to mention that although not all features 
of solid cancers, such as the influence of stroma and 
immune  cells,  are  modeled  by  multicellular  sphe-
roids, spheroids do reflect many important properties 
of solid tumors, including the development of an ex-
tracellular matrix, tight junctions  between epithelial 
cells, and gradients of nutrient concentration and cell 
proliferation from the exterior to the center. Spheroids  Journal of Cancer 2011, 2 
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can develop central necrosis and regions of hypoxia. 
By incubating spheroids with an anticancer drug, it 
then becomes possible to examine the kinetics of drug 
penetration. Unlike a previous method12, the protocol 
described  here  is  relatively  simple  and  straightfor-
ward to learn, rapid in producing samples, and eco-
nomically feasible. 
Experimental Design 
NCI-H226 (American Type Culture Collection or 
ATCC,  Rockville,  MD)  is  a  human  lung  squamous 
carcinoma  cell  line.  HepG2  and  Hep3B (ATCC)  are 
two human liver cancer (HCC) cell lines. NCI-M-03 
and NCI-M-13 (Raffit Hassan, NCI, Bethesda, MD) are 
two human mesothelioma primary cell lines isolated 
from the ascites of malignant mesothelioma patients 
treated at the NCI.8 
 
MATERIALS  
REAGENTS FOR FORMATION OF 
SPHEROIDS 
  Poly-HEMA (Sigma; Cat. #P3932) 
  95% ethanol (in milliQ water) 
  U-bottomed  96-well  plates  (Greiner;  Cat. 
#650185) 
  SS1P (Ira Pastan, Laboratory of Molecular Biol-
ogy, NCI, Bethesda, MD)  
  RPMI 1640 Media (Invitrogen; Cat. #21870-076) 
containing  10%  fetal  bovine  serum  (FBS),  1% 
L-glutamine (Invitrogen, Carlsbad, CA) and 1% 
penicillin-streptomycin  (Invitrogen,  Carlsbad, 
CA) 
  FreeStyle  293  Media  (Invitrogen;  Cat. 
#12338-018) 
  Accutase (BD Biosciences; Cat. #561527) 
  T-75cm2  tissue  culture  flasks  (Sarstedt;  Cat. 
#83.1813.002) 
ADDITIONAL REAGENTS FOR 
CHARCTERIZATION OF SPHEROIDS 
  Coomassie Plus Protein Assay Reagent (Thermo 
Scientific; Cat. #1856210) 
  RNeasy Mini Kit (Qiagen; Cat. #74104)  
  Cell Counting Kit-8 (Dojindo Laboratories; Cat. 
#CK04) 
  Costar white opaque-walled 96-well plates ade-
quate for cell culture (Corning; Cat. #3922) 
  CellTiter-Glo  Luminescent  Cell  Viability  Assay 
(Promega; Cat. #G7572) 
REAGENT SETUP 
Lysis buffer  
To make a stock solution of lysis buffer, combine 
one  “Complete  Mini-EDTA  free”  protease  inhibitor 
tablet (Roche; Cat. #1873580), 10 mL of RIPA buffer, 
and 1 mL of 20% SDS. 
Poly-HEMA  
Prepare  a  120  mg/mL  stock  solution  of 
poly-HEMA in 95% ethanol. Incubate while stirring 
with  a  sterile  magnetic  bar  at  room  temperature 
(15–20°C) overnight. To make a working solution of 
Poly-HEMA, pipette 1 mL of Poly-HEMA stock solu-
tion into 23 mL of 95% ethanol to obtain a final con-
centration of 5 mg/mL (this volume is enough to coat 
four plates). Vortex solution and leave at room tem-
perature (15–20°C) until ready to coat. Prepare fresh 
working solution every time new plates are made. 
EQUIPMENT 
Device (plate shaker) for mixing multiwell plates 
Luminometer  or  charge-coupled  device  (CCD) 
camera imaging device capable of reading multiwell 
plates 
PROCEDURE  
Preparation of non-adsorbent poly-HEMA 
plates  
1  Pipette 60 μL of poly-HEMA stock solution 
into each well of a 96-well U-bottomed plate. 
SEE TROUBLESHOOTING (1) 
2  Evaporate with lids on at room tempera-
ture (15–20°C) inside a sterile hood for 72 hours. 
SEE TROUBLESHOOTING (2) 
3  After plates are completely dried, seal with 
parafilm, and store at 4ºC.  
4  Before  use,  bring  to  room  temperature 
(15-20ºC) and sterilize in the hood with lids off for 30 
minutes.  
Preparation of Spheroids 
5  Maintain  cell  line  as  adherent  monolayer 
cultures  in  RPMI  1640  medium  supplemented  with 
10% FBS, L-glutamine, and penicillin-streptomycin. 
6  Incubate at 5% CO2 with balance of air at 
37°C.  
7  Seed  at  2x105cells/mL  in  T-75cm2  tissue 
culture flasks. 
8  Change cell media twice a week.  
9  Rinse the cells with PBS and add 5 mL of 
Accutase to detach cells and incubate at 37°C for 3-5 
minutes.  Journal of Cancer 2011, 2 
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10  Neutralize with 5 mL of growth media and 
perform a cell count. 
11  Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes. 
12  Dilute cell concentration to 5x104 cells/mL 
with growth media in order to form 10,000-cells per 
well  spheroids  (approximately  1  million  cells  are 
needed per plate). 
13  Pipette 200 µL of the cell suspension into 
each  well  of  the  96-well  plate  pre-coated  with 
poly-HEMA. 
14  Centrifuge  the  plate  at  216  x  g  at  room 
temperature (15–20°C) for 10 minutes. 
15  Incubate for 24-48 hours at 37°C, 5% CO2. 
SEE TROUBLESHOOTING (3) 
Preparation of Cell Lysate from Spheroids and 
Monolayers 
Spheroids 
16  Pipette growth media and spheroid com-
pletely from each well and collect in a 50 mL tube. 
17  Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, aspirate the supernatant, and 
resuspend the cells with 1.5 mL of PBS. 
18  Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, aspirate the supernatant, and 
resuspend the cells in 50 µL of lysis buffer (for ap-
proximately 1 million cells). 
19  Vortex thoroughly. 
20  Repeat four cycles of freezing at 80ºC for 
approximately  10  minutes  and  thawing  at  37ºC  for 
approximately 20 minutes. 
21  Centrifuge at 216 x g at room temperature 
(15–20°C) for 1 minute, and collect all of the superna-
tant. 
22  Measure concentration by Coomassie stain, 
a  reliable  standard  for  protein  quantification.  Load 
approximately 50-100 µg of cell protein lysate per lane 
for western blot analysis. 
Monolayers 
23  Aspirate growth media of monolayer cells 
and rinse three times with PBS. 
Δ  CRITICAL  STEP  Allow  monolayer  cells  to 
grow for two to three days after seeding until 50-60% 
confluent. 
24  Add  2  mL  of  PBS  and  scrape  monolayer 
cells on ice, and collect in a 15 mL tube.  
25  Add  another  2  mL  of  PBS  to  the  plate, 
scrape, and collect the remaining cells. 
26  Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, aspirate the supernatant, and 
resuspend the cells in 50 µL of lysis buffer (for ap-
proximately 1 million cells) 
27  Vortex thoroughly.  
28  Repeat four cycles of freezing and thawing 
(-80º/37ºC). 
29  Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, and collect all supernatant. 
30  Measure concentration by Coomassie stain. 
Load approximately 50-100 µg of cell protein lysate 
per lane for western blot analysis. 
SEE TROUBLESHOOTING (4) 
Purification of RNA for Microarray Analysis 
31  Collect monolayer and spheroid cell lysate 
on three separate days. 
Δ CRITICAL STEP Save a sufficient amount of 
cell lysate for RNA quality validation. 
32  Follow  manufacturer’s  kit  instructions  to 
purify RNA. 
SEE TROUBLESHOOTING (5) 
WST Assay 
33  Form  3D  spheroids  on  a  96-well 
poly-HEMA-coated plate. 
34  Allow monolayers and spheroids to grow 
for 24 hours. 
35  Add  20  µL  of  SS1P/BL22  (negative  con-
trol)/Cycloheximide (CMH) (positive control) to 200 
µL of RPMI growth media per well for a 1:10 dilution. 
SEE TROUBLESHOOTING (6) 
36  Allow monolayers and spheroids to incu-
bate for 72 hours with immunotoxin. 
37  Prepare  a  sufficient  volume  of  WST  rea-
gent in serum-free FreeStyle media (e.g. 1 mL of rea-
gent in 9 mL of media). 
38  Remove  growth  media  and  replace  with 
100 µL/well of a working solution of WST reagent- 
FreeStyle media mentioned in the previous step. 
39  Transfer all 100 µL containing each sphe-
roid from each well to a flat-bottom 96-well plate. 
40  Allow to incubate for 2-4 hours at 37ºC un-
til brown-yellow color develops. 
41  Measure absorbance at 450 nm with refer-
ence wavelength of 650 nm. 
ATP Assay 
42  Form  3D  spheroids  on  a  96-well 
poly-HEMA coated plate. 
43  Allow monolayers and spheroids to grow 
for 24 hours. 
44  Seed 10,000 cells/well for monolayer cells 
and one 10,000-cell spheroid/well containing 200 µL 
of RPMI growth media in a 96-well flat bottom plate. 
45  Add  20  µL  of  SS1P  and  BL22  (negative 
control) from 1000 ng/mL to 0.0001 ng/mL to each 
well.  Journal of Cancer 2011, 2 
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SEE TROUBLESHOOTING (7) 
46  Incubate for 72 hours at 37ºC. 
47  Transfer monolayer cells and spheroids via 
a pipette to opaque-walled multiwell plates in culture 
medium (100 µL/well for 96-well plates). 
48  Prepare control wells containing medium 
without  cells  to  obtain  background  luminescence 
value. 
49  Equilibrate  the  plate  and  its  contents  at 
room  temperature  (15-20ºC)  for  approximately  30 
minutes. 
50   Add  a  volume  of  CellTiter-Glo  Reagent 
equal to the volume of cell culture medium present in 
each well (e.g., add 100 µL of reagent to 100 µL of 
growth media containing cells for a 96-well plate). 
51  Mix contents for 2  minutes on an  orbital 
shaker to induce cell lysis. 
52  Allow plate to incubate at room tempera-
ture (15-20ºC) for 10 minutes to stabilize luminescent 
signal. 
53  Measure luminescence. 
SEE TROUBLESHOOTING (8) 
TROUBLESHOOTING 
1.  For  proper  storage,  the  stock  solution  of 
poly-HEMA  can  be  stored  at  room  temperature 
(15-20ºC) indefinitely. 
2.  It is optional to evaporate with the lids on 
at room temperature (15–20°C) on the bench for 1 to 2 
weeks for slower drying, or to evaporate at 37°C in-
side a humidity-free bacterial incubator for 48 hours.  
3.  Within six hours, mesothelioma cells begin 
to form as an aggregate and should be left alone as 
they  may  be  easily  disturbed  by  pipetting.  By  24 
hours, most mesothelioma cells form into a disk-like 
shape  called  a  multicellular  spheroid  and  can  be 
transferred gently by a pipette without dissociating. 
4.  For proteins that may be more difficult to 
visualize or detect (e.g. E-Cadherin), use at least 100 
µg  of  cell  protein  lysate  per  lane  for  western  blot 
analysis. 
5.  Selected GeneChip Human Genome U133 
Plus  2.0  Array  was  performed  by  NCI  Affymetrix 
Group  (Frederick,  MD)  for  reliability.  For  optimal 
results, the recommended final concentration of RNA 
for array analysis is 100 ng/mL in a 6 µL volume per 
sample. 
6.  To  properly  prepare  SS1P  at  the  original 
concentration  (0.25  mg/mL):  For  100  ng/mL  final 
concentration, add 20 µL of 1 µg/mL SS1P into 100 µL 
growth  media  per  well.  For  1000  ng/mL  final  con-
centration,  add  20µl  of  10µg/ml  SS1P  into  200µl 
growth  media  per  well.  Original  concentration  of 
BL22 (1 µg/mL): For 100 ng/mL final concentration, 
add 20 µL of 1 µg/mL BL22 into 200 µL growth media 
per  well.  Original  concentration  of  CHM  (100 
µg/mL): For working solution, dilute 1 µL in 99 µL of 
growth media. For 1:1000 final concentration, add 20 
µL of CHM working solution into 200 µL growth me-
dia per well. 
7.  To  properly  prepare  SS1P  at  the  original 
concentration (0.25 mg/mL): Dilute to 10,000 ng/mL 
working solution (adding 20 µL of this in 200 µL of 
cell suspension results in a final concentration of 1000 
ng/mL). For a 1000 ng/mL working solution, add 100 
µL of 10,000 ng/mL SS1P in 900 µL of growth media 
(adding 20 µL of this in 200 µL of cell suspension re-
sults in a final concentration of 100 ng/mL). Continue 
to serially dilute 100 µL of SS1P in 900 µL of growth 
media. Original concentration of BL22 (684 µg/mL): 
Dilute to 10,000 ng/mL working solution (adding 20 
µL of this in 200 µL of cell suspension results in a final 
concentration  of  1000  ng/mL).  For  a  1000  ng/mL 
working solution, add 100 µL of 10,000 ng/mL BL22 
in 900 µL of growth media (adding 20 µL of this in 200 
µL of cell suspension results in a final concentration of 
100  ng/mL).  Continue  to  serially  dilute  100  µL  of 
BL22 in 900 µL of growth media. 
 8.  It is highly recommended to do more than 
one type of cell proliferation or viability assay (e.g. 
WST and ATP). 
TIMING 
Step  1-4,  Preparation  of  non-adsorbent 
Poly-HEMA plates: 3 days 
Step 5-15, Preparation of Spheroids: 2 days 
Step 16-30,  Preparation of Cell Lysate: 3 hours 
Step 31-32, Purification of RNA for Microarray 
Analysis: 1 day 
Step 33-41, WST Assay for SS1P-Treated Mono-
layers and Spheroids: 4 days 
Step 42-53, ATP Assay for SS1P-Treated Mono-
layers and Spheroids: 4 days 
ANTICIPATED RESULTS 
Using the experimental conditions described in 
this protocol, almost all of the established cancer cell 
lines and primary cells isolated from patients are able 
to form 3D spheroids in vitro (Fig. 2). We found that 
the  mesothelioma  and  HCC  cells  we  used  formed 
spheroids well.   
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Figure 2. Establishment of in vitro tumor spheroids. Microscopic images of monolayers and spheroids of human 
cancer cell lines, NCI-H226 (mesothelioma), HepG2 (hepatocellular carcinoma or HCC), Hep3B (HCC), and primary 
mesothelioma lines, NCI-M-03 and NCI-M-13, isolated from patients taken after 24 hours. Scale bars, 400 µm. 
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Within only 2 days after seeding cells, spheroids 
are ready for tumor penetration studies of antibodies 
or immunoconjugates, RNA extraction for microarray 
analysis, protein lysis for proteomics analysis or dis-
covery of tumor penetration antibodies by phage dis-
play and other antibody technologies. 
To  investigate  how  tumor  microenvironments 
affect the killing activity and penetration of an anti-
body agent, monolayers and spheroids were treated 
with SS1P and a negative control. Cell growth inhibi-
tion  (WST)  and  cell  viability  (ATP)  assays  showed 
that the IC50 of SS1P for spheroids was >1000 ng/mL, 
at least 100 times the IC50 for monolayers, ~10 ng/mL, 
after 72 hours. Both assays revealed that greater than 
50% of the cancer cells from spheroids could not be 
killed by SS1P concentrations as high as 1,000 ng/mL. 
Finally, we tested SS1P on primary lines isolated from 
malignant mesothelioma patients and confirmed that 
SS1P was far less effective on spheroids. 
We  explored  two  different  experimental  ap-
proaches to examine the roles of protein regulation in 
regard  to  immunotoxin  penetration.  The  first  in-
volved silencing E-Cadherin using siRNA. A reduc-
tion in protein expression (greater than 80%) was ob-
served followed by an increased sensitization to SS1P 
therapy.  Finally,  an  inhibitory  antibody  against 
E-Cadherin  also  demonstrated  enhanced  anti-tumor 
activity only if added before, but not after, spheroid 
formation. 
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